December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
All News
Headline News
Press Releases
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Zai Lab Announces Changes to Senior Leadership Team
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
KBRA Assigns AA- Rating to Miami-Dade County, FL Aviation Revenue Refunding Bonds; Outlook Positive
From Kroll Bond Rating Agency, LLC
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
From Veracyte
Via Business Wire
Tickers VCYT
News headline image
Conduent Announces Agreement to Sell Its Public Transit Business to Modaxo for $164 Million
From Conduent Incorporated
Via Business Wire
Tickers CNDT
News headline image
Halliburton Announces Dividend
From Halliburton Company
Via Business Wire
Tickers HAL
News headline image
MSCI Announces Dates for 2026 Annual Market Classification and Accessibility Reviews
From MSCI Inc.
Via Business Wire
Tickers MSCI
News headline image
FCPT Announces Acquisition of a Gerber Collision Property for $3.5 Million
From Four Corners Property Trust
Via Business Wire
Tickers FCPT
News headline image
NUAI INVESTOR REMINDER: New Era Energy & Digital, Inc. Investors Have Until June 1, 2026 To Seek Lead Plaintiff Role - Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
Tickers NUAI
News headline image
80% of Individual Contributors Say Their Manager’s Approach to AI is Hands-Off, FranklinCovey Research Finds
From FranklinCovey
Via Business Wire
Tickers FC
News headline image
Logitech Files Annual Report on Form 10-K
From Logitech International
Via Business Wire
Tickers LOGI
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
Tickers NTRA
News headline image
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
From Aulos Bioscience
Via Business Wire
News headline image
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Tickers FLGT
News headline image
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Dell Technologies to Present at Investor Conference in June
From Dell Technologies
Via Business Wire
Tickers DELL
News headline image
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
From 858 Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Tickers BCYC
News headline image
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
Tickers AGEN
News headline image
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
From Artera
Via Business Wire
News headline image
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
From A2 Biotherapeutics, Inc.
Via Business Wire
News headline image
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
From Convergent Therapeutics Inc.
Via Business Wire
News headline image
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
From City of Hope
Via Business Wire
News headline image
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
From Flatiron Health
Via Business Wire
News headline image
Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)
From Ingenia Therapeutics
Via Business Wire
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
News headline image
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
From Agenus Inc.
Via Business Wire
Tickers AGEN
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.